Alvogen and Pfenex’s PF708 (biosimilar, teriparatide) Receives FDA’s Approval for the Treatment of Osteoporosis

 Alvogen and Pfenex’s PF708 (biosimilar, teriparatide) Receives FDA’s Approval for the Treatment of Osteoporosis

Alvogen and Pfenex’ PF708 (biosimilar, teriparatide) Receives FDA’s Approval for the Treatment of Osteoporosis

Shots:

  • The US FDA has granted approval to PF708, a biosimilar of Eli Lilly’s Forteo (teriparatide injection) under the 505(b)(2) regulatory pathway for the treatment of osteoporosis in certain patients at high risk for fracture
  • Pfenex will receive a $2.5M milestone from Alvogen on its approval in the US. The PF708 is the first approved product of Pfenex, validating Pfenex Expression Technology platform and enhances patient’s access to a cost-effective alternative to Forteo
  • Pfenex is conducting a comparative human factors study between PF708 and Forteo, evaluating the therapeutic equivalence of both the therapies with its anticipated submission by the end of Oct’19

Click here to­ read full press release/ article | Ref: PRNewswire | Image: Pfenex

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post